RBC Capital raised the firm’s price target on Exact Sciences (EXAS) to $54 from $52 and keeps a Sector Perform rating on the shares after its Q1 results. The quarter has ushered the launch of Cologuard Plus and Oncodetect, keeping successful products center to the FY25 story, the analyst tells investors in a research note. The company’s pipeline updates like the BLUE-C readout in Summer of 2025 and second half’s CancerGuard launch provide key catalysts through the year, RBC adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Exact Sciences price target raised to $72 from $69 at Baird
- Exact Sciences: Strong Q1 Performance and Promising Prospects Justify Buy Rating
- Exact Sciences price target raised to $75 from $55 at Barclays
- Exact Sciences Reports Strong Q1 2025 Results
- Closing Bell Movers: Apple and Amazon slip after earnings